临床试验/PER-019-04

PER-019-04已完成未知

STUDY PHASE IV RANDOMIZED, OPEN, MULTICENTER, TO EVALUATE THE ANTIVIRAL EFFICACY AND SAFETY OF ATAZANAVIR WITH AND WITHOUT RITONAVIR IN COMBINATION WITH LAMIVUDINE AND STADUVINA OF PROLONGED RELEASE IN VIRGIN PATIENTS OF ANTIRETROVIRAL TREATMENT

BRISTOL MYERS SQUIBB COMPANY,0 个研究点目标入组 0 人开始时间: 2004年5月5日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方: BRISTOL MYERS SQUIBB COMPANY,

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 0（—）

入选标准

•Signed Informed Consent
•HIV RNA greater than or equal 200 copies/mL at screening
•18 years old or older
•Must use barrier contraception
•Women of child-bearing potential must have a negative serum or urine pregnancy test within 72 hours before beginning to take the study medications

排除标准

•Unable or unwilling to use acceptable method of birth control for the entire study period including 8 weeks after the study
•Women using oral contraceptives, pregnant or breastfeeding women
•Women who have a positive pregnancy test on enrollment or before beginning to take the study medications
•People who have a life expectancy of greater than 12 months
•Newly diagnosed HIV-related OI or any medical condition requiring acute therapy at the time of enrollment
•Any antiretroviral therapy within 30 days prior to screening

研究者

发起方

BRISTOL MYERS SQUIBB COMPANY,

相似试验

进行中（未招募）

Open, multicenter and randomized study phase IV to evaluate the efficacy and safety of 24 weeks more of treatment in patients with chronic hepatitis C genotype 1 and/or 4 co-infected with human inmmunodeficiency virus - Treatment of co-infected HIV/HCV patients genotype 1/4 24 weeks more than standar duratioChronic hepatitis C

EUCTR2004-004948-45-ESJosé Hernández-Quero. Hospital Clínico San Cecilio

进行中（未招募）

24 weeks vs. 48 weeks of treatment of coinfected HIV/HCV patients genotype II-IIIHepatitis C

EUCTR2005-000203-34-ESEnrique Ortega González186

进行中（未招募）

Estudio de fase IV, multicéntrico, aleatorizado y doble ciego para comparar la seguridad y eficacia de 180 µg de Pegasys® más 1000 ó 1200 mg de Copegus® con la combinación actualmente aprobada de 180 µg de Pegasys® más 800 mg de Copegus® en pacientes con infección por el virus de la hepatitis C crónica del genotipo 1 coinfectados con el virus de la inmunodeficiencia humana (VIH-1), que no hayan sido previamente tratados con interferón.

EUCTR2005-005506-23-ESF. Hoffmann-La Roche Ltd400

RANDOMIZED, MULTICENTER, OPEN, PHASE III,STUDY OF LAPATINIB, TRASTUZUMAB AND ITS COMBINATION IN NEOADYUVANCIA MORE PACLITAXEL IN WOMEN WITH PRIMARY BREAST CANCER HER2 / ERBB2 POSITIVE-C509 Breast, unspecifiedBreast, unspecifiedC509

PER-089-07OVARTIS BIOSCIENSES PERU S.A.,38

进行中（未招募）

Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)

EUCTR2005-001026-89-DESerono GmbH100